A De-Escalating Strategy for Antibiotic Treatment of Pneumonia in The Medical Intensive Care Unit (0787B-092)

The primary objective of this study is a comparison between MK0787B and standard therapy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Infection Infections Lung Diseases Pneumonia Respiratory Tract Diseases Respiratory Tract Infections

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Greater than 18 years of age
Patient is diagnosed with nosocomial pneumonia

Exclusion criteria

Immunological deficient patients
Pregnant women and nursing mothers
A fungus is identified before the study enrollment
Received vancomycin or imipenem for more than 5 days before icu admission

Treatment and study plan

MK0787B, imipenem/cilastatin sodium / Duration of Treatment: 7 Days

Drug

Comparator: amikacin / Duration of Treatment: 3 Days

Drug

Comparator: tazocin / Duration of Treatment: 3 Days

Drug

Comparator: vancomycin / Duration of Treatment: 3 Days

Drug

Primary outcomes

A 30-day-survival rate in the intensive care unit evaluated by Acute Physiology and Chronic Health (APACH II) Disease Classification System II score

Sponsors and collaborators

Lead sponsor

Merck Sharp & Dohme LLC

Industry

Registry information

Official study title

A De-Escalating Strategy for Antibiotic Treatment of Pneumonia in The Medical Intensive Care Unit

Important dates

Study start: 2006
Primary completion: 2007
Study completion: 2007
First posted: Mar 8, 2007
Registry last updated: Feb 17, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed